417 related articles for article (PubMed ID: 20385723)
1. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.
Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J
Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723
[TBL] [Abstract][Full Text] [Related]
2. Differential gene expression in ACTH -secreting and non-functioning pituitary tumors.
Tateno T; Izumiyama H; Doi M; Yoshimoto T; Shichiri M; Inoshita N; Oyama K; Yamada S; Hirata Y
Eur J Endocrinol; 2007 Dec; 157(6):717-24. PubMed ID: 18057378
[TBL] [Abstract][Full Text] [Related]
3. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
[TBL] [Abstract][Full Text] [Related]
4. Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma.
Tateno T; Izumiyama H; Doi M; Akashi T; Ohno K; Hirata Y
Endocr J; 2007 Dec; 54(5):777-82. PubMed ID: 17917309
[TBL] [Abstract][Full Text] [Related]
5. Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.
Zhang K; Shou X; Chen H; Qiao N; He W; Chen Z; Shen M; Li S; Zhao Y; Zhang Z; Li Y; Ye H; Wang Y
Front Endocrinol (Lausanne); 2020; 11():608691. PubMed ID: 33584540
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review].
Kageyama K; Oki Y; Nigawara T; Suda T; Daimon M
Endocr J; 2014; 61(10):941-8. PubMed ID: 24974880
[TBL] [Abstract][Full Text] [Related]
7. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.
Langlois F; Lim DST; Yedinak CG; Cetas I; McCartney S; Cetas J; Dogan A; Fleseriu M
Pituitary; 2018 Feb; 21(1):32-40. PubMed ID: 29032459
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.
Iino K; Oki Y; Matsushita F; Yamashita M; Hayashi C; Miura K; Nishizawa S; Nakamura H
Pituitary; 2007; 10(1):35-45. PubMed ID: 17410413
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas.
Jahangiri A; Wagner JR; Pekmezci M; Hiniker A; Chang EF; Kunwar S; Blevins L; Aghi MK
Neurosurgery; 2013 Jul; 73(1):8-17; discussion 17-8. PubMed ID: 23685641
[TBL] [Abstract][Full Text] [Related]
10. Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease.
Tabuchi Y; Kitamura T; Fukuhara A; Mukai K; Onodera T; Miyata Y; Hamasaki T; Oshino S; Saitoh Y; Morii E; Otsuki M; Shimomura I
Endocr J; 2016 Jun; 63(6):545-54. PubMed ID: 27025408
[TBL] [Abstract][Full Text] [Related]
11. Cushing's disease associated with both pituitary microadenoma and corticotroph hyperplasia.
Haap M; Gallwitz B; Meyermann R; Mittelbronn M
Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):289-93. PubMed ID: 19085700
[TBL] [Abstract][Full Text] [Related]
12. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
[TBL] [Abstract][Full Text] [Related]
13. Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas.
Kim D; Ku CR; Park SH; Moon JH; Kim EH; Kim SH; Lee EJ
World Neurosurg; 2018 Jul; 115():e464-e471. PubMed ID: 29678704
[TBL] [Abstract][Full Text] [Related]
14. Complications after transsphenoidal surgery for patients with Cushing's disease and silent corticotroph adenomas.
Smith TR; Hulou MM; Huang KT; Nery B; de Moura SM; Cote DJ; Laws ER
Neurosurg Focus; 2015 Feb; 38(2):E12. PubMed ID: 25639314
[TBL] [Abstract][Full Text] [Related]
15. Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review.
Zheng G; Lu L; Zhu H; You H; Feng M; Liu X; Dai C; Yao Y; Wang R; Zhang H; Sun X; Lu Z
Front Endocrinol (Lausanne); 2020; 11():558593. PubMed ID: 33071973
[No Abstract] [Full Text] [Related]
16. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
17. The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3.
Righi A; Faustini-Fustini M; Morandi L; Monti V; Asioli S; Mazzatenta D; Bacci A; Foschini MP
Endocrine; 2017 May; 56(2):286-297. PubMed ID: 27491554
[TBL] [Abstract][Full Text] [Related]
18. Perioperative hypothalamic pituitary adrenal function in patients with silent corticotroph adenomas.
Cheres AF; ElAsmar N; Rajpal A; Selman WR; Arafah BM
Pituitary; 2017 Aug; 20(4):471-476. PubMed ID: 28528397
[TBL] [Abstract][Full Text] [Related]
19. Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas.
Pecori Giraldi F; Cassarino MF; Sesta A; Lasio G; Losa M
Neuroendocrinology; 2023; 113(6):606-614. PubMed ID: 36791678
[TBL] [Abstract][Full Text] [Related]
20. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.
Hayashi K; Inoshita N; Kawaguchi K; Ibrahim Ardisasmita A; Suzuki H; Fukuhara N; Okada M; Nishioka H; Takeuchi Y; Komada M; Takeshita A; Yamada S
Eur J Endocrinol; 2016 Feb; 174(2):213-26. PubMed ID: 26578638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
